Ultimovacs – executive interview

Ultimovacs – executive interview

Ultimovacs — 7 videos in collection

More on this equity

Ultimovacs is a biotechnology company developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT). Around 85% of all cancer types express high levels of hTERT. Therefore, UV1 has broad potential in a variety of different settings and combinations with other cancer treatments.

In this video, chief executive officer Carlos de Sousa reviews the company’s broad R&D pipeline and explains multiple upcoming catalysts.


You may also be interested in these:

Healthcare

Ultimovacs – executive interview

Ultimovacs

Healthcare

Ultimovacs - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free